Announcing a new publication for Acta Materia Medica journal. Viral infections represent a major threat to human health and the global economy; however, most of the currently available antiviral drugs are not fully effective in restricting viral replication and selecting for drug-resistant variants. Targeted protein degradation technologies are promising strategies to avoid or delay the emergence of drug resistance. Among the protein degradation-based multi-specific approaches, proteolysis targeting chimera (PROTAC) is the main strategy applied in the antiviral field. In this article the authors discuss the elements and mechanisms of action used by PROTAC technology, as well as the advantages of PROTACs over available antiviral drugs. The latest progress in the application of PROTACs in antiviral research, existing challenges and future opportunities for antiviral drug discovery are also discussed.
# # # # # #
Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.
Submissions to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at https://mc04.manuscriptcentral.com/ammed
Queries about the journal can be sent to firstname.lastname@example.org.
Please visit https://amm-journal.org/ to learn more about the journal.
Editorial Board: https://amm-journal.org/index.php/editorial-board/
There are no author submission or article processing fees.
# # # # # #
Yang Zhou, Shujing Xu and Nerea López-Carrobles et al. Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality. Acta Materia Medica. 2023. Vol. 2(3):285-298. DOI: 10.15212/AMM-2023-0019